Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

181. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate

to methylphenidate may not be reliable. Implications of the review for practice and research Practice : The authors did not state any implications for practice. Research : The authors indicated that more high-quality trials of traditional Chinese medicine for treatment of children with ADHD were needed. Funding Not stated. Bibliographic details Lan Y, Zhang LL, Luo R. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate. Journal (...) Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Lan Y, Zhang LL, Luo R CRD summary This review identified trials of traditional Chinese medicine compared

2009 DARE.

182. Review: prevalence of adult ADHD declines with age

? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: prevalence of adult ADHD declines with age Article Text Prevalence Review: prevalence of adult ADHD declines with age Statistics from Altmetric.com Question Question: What is the prevalence of adult attention deficit hyperactivity disorder (ADHD) and which factors have (...) in special groups (eg, people with bipolar or panic disorder) were excluded, as were family studies, follow-up studies and studies not using DSM-IV criteria to diagnose adult ADHD. A mixed effect meta-regression was applied to estimate the prevalence of ADHD and to assess the impact of demographic variables on the estimates of prevalence. Main results Six studies met inclusion criteria and were included in the meta-analysis. Prevalence of adult ADHD … Request Permissions If you wish to reuse any or all

2009 Evidence-Based Mental Health

183. Atomoxetine for ADHD in Children and Adolescents

Atomoxetine for ADHD in Children and Adolescents [73] Atomoxetine for ADHD in Children and Adolescents | Therapeutics Initiative Independent Healthcare Evidence > > [73] Atomoxetine for ADHD in Children and Adolescents In Letter #69 we summarized the evidence for the CNS stimulants, methylphenidate, dextroamphetamine and mixed amphetamine salts, to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and concluded “Better benefit and harm evidence is necessary before long-term CNS (...) SSF, Huang Y-S, Soong W-T, Chou M-C et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine hydrochloride in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Pyschopharmacology 2007; 17(4):447-460. Kelsey DK, Sumner CR, Casat CD et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double

2009 Therapeutics Letter

184. [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder]

[Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Evaluacion de la situacion asistencial y recomendaciones terapeuticas en el trastorno por deficit de atencion e hiperactividad [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Evaluacion de la situacion asistencial y recomendaciones terapeuticas en el trastorno por deficit de atencion e hiperactividad (...) [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Lasa-Zulueta Alberto, Jorquera-Cuevas Cristina Citation Lasa-Zulueta Alberto, Jorquera-Cuevas Cristina. Evaluacion de la situacion asistencial y recomendaciones terapeuticas en el trastorno por deficit de atencion e hiperactividad. [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Vitoria-Gasteiz: Basque Office for Health

2009 Health Technology Assessment (HTA) Database.

185. Stimulants for Attention-Deficit/Hyperactivity Disorder (ADHD) in children

Stimulants for Attention-Deficit/Hyperactivity Disorder (ADHD) in children Stimulants for Attention-Deficit/Hyperactivity Disorder (ADHD) in children Stimulants for Attention-Deficit/Hyperactivity Disorder (ADHD) in children Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Stimulants for Attention-Deficit/Hyperactivity Disorder (...) (ADHD) in children . Lansdale: HAYES, Inc.. 2009 Authors' objectives Attention-deficit hyperactivity disorder (ADHD) is a common disorder of childhood and adolescence that is characterized by symptoms of inattention and/or hyperactivity/impulsivity with symptoms persisting for at least 6 months and to an extent that is maladaptive and inconsistent with developmental level. Stimulant medications are widely used for the treatment of ADHD in children and adults. Project page URL Indexing Status Subject

2009 Health Technology Assessment (HTA) Database.

186. Nonpharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Children:Behavior Therapy

database. Report may be purchased from . Citation Nonpharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Children:Behavior Therapy . Lansdale: HAYES, Inc.. 2009 Authors' objectives Behavior therapy (BT) for attention-deficit hyperactivity disorder (ADHD) was developed as a way to increase desirable behaviors and reduce or eliminate the undesirable behaviors and tendencies associated with ADHD, including disruptive behavior, poor social skills, poor academic performance (...) Nonpharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Children:Behavior Therapy Nonpharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Children:Behavior Therapy Nonpharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Children:Behavior Therapy Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA

2009 Health Technology Assessment (HTA) Database.

187. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) - a pharmacoepidemiological and qualitative study

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) - a pharmacoepidemiological and qualitative study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 Health Technology Assessment (HTA) Database.

188. Nonpharmacological treatments for attention-deficit/hyperactivity disorder (ADHD): Neurofeedback

. Citation Nonpharmacological treatments for attention-deficit/hyperactivity disorder (ADHD): Neurofeedback . Lansdale: HAYES, Inc.. 2009 Authors' objectives Neurofeedback for attention-deficit/hyperactivity disorder (ADHD) is used to teach patients to regulate brain activity that appears impaired in ADHD. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Diets Language Published English Country of organisation United (...) Nonpharmacological treatments for attention-deficit/hyperactivity disorder (ADHD): Neurofeedback Nonpharmacological treatments for attention-deficit/hyperactivity disorder (ADHD): Neurofeedback Nonpharmacological treatments for attention-deficit/hyperactivity disorder (ADHD): Neurofeedback Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from

2009 Health Technology Assessment (HTA) Database.

189. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Full Text available with Trip Pro

(both immediate and extended release) or no treatment, in Spanish children with attention deficit hyperactivity disorder (ADHD). Interventions Methylphenidate, a mild stimulant and the most common treatment for children with ADHD, was compared with atomoxetine, a new non-stimulant alternative, in Spain. The study also compared no medication to capture those patients who could not receive stimulant medication due to a previous adverse experience or co-morbidities. Three populations were evaluated (...) A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Hong J, Dilla T, Arellano

2009 NHS Economic Evaluation Database.

190. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

Health Service. The methodology was valid, but most of the details of the methods and results were published in another paper. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-utility analysis Study objective This study was an economic evaluation of atomoxetine for children with attention deficit and hyperactivity disorder (ADHD) compared with alternative treatments, such as psychostimulants, in various subgroups of patients depending on their previous treatment history (...) Cottrell S, Tilden D, Robinson P, et al. A modelled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value in Health 2008; 11(3): 376-388. Prasad S, Harpin V, Poole L. A multi-centre, randomised, open-label study of atomoxetine with standard current therapy in UK children and adolescents with ADHD. Current Medical Research and Opinion 2007; 23: 379-394. Indexing Status Subject indexing

2009 NHS Economic Evaluation Database.

191. Early head injury and attention deficit hyperactivity disorder: retrospective cohort study. Full Text available with Trip Pro

Early head injury and attention deficit hyperactivity disorder: retrospective cohort study. To explore the hypothesis that medically attended head injury in young children may be causal in the later development of attention deficit hyperactivity disorder.Retrospective cohort study.Health improvement network database (1988-2003), a longitudinal UK general practice dataset.All children registered in the database from birth until their 10th birthday.Risk of a child with a head injury before age 2 (...) developing attention deficit hyperactivity disorder before age 10 compared with children with a burn injury before age 2 and children with neither a burn nor a head injury.Of the 62 088 children who comprised the cohort, 2782 (4.5%) had a head injury and 1116 (1.8%) had a burn injury. The risk of diagnosis of attention deficit hyperactivity disorder before 10 years of age after adjustment for sex, prematurity, socioeconomic status, and practice identification number was similar in the head injury

2008 BMJ

192. Mixed amphetamine salts - Attention deficit hyperactivity disorder

Advisory Committee had previously recommended that Adderall XR not be listed (see Notice of CEDAC Final Recommendation on Adderall XR issued on November 24, 2004). A new indication for use in adolescents and adults and new clinical trial information in children were the basis for the resubmission. Adderall XR is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Dosage Forms: Capsules containing both immediate and extended release pellets of mixed amphetamine salts: 5 mg, 10 (...) Mixed amphetamine salts - Attention deficit hyperactivity disorder Common Drug Review CEDAC Meeting – April 16, 2008; CEDAC Reconsideration – June 18, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – June 25, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION MIXED AMPHETAMINE SALTS (Adderall XR ® – Shire Canada Inc.) Description: Adderall XR ® contains dextroamphetamine and levoamphetamine salts in a 3:1 ratio. The Canadian Expert Drug

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

193. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder (Abstract)

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder Children with attention-deficit/hyperactivity disorder often have varying needs for coverage of their symptoms throughout the day. The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD.Methylphenidate dose was optimized over 5 weeks (...) using 10-, 15-, 20-, or 30-mg patches worn for 9 hours. The efficacy of 4- and 6-hour wear times was then assessed in an Analog Classroom setting during a randomized, placebo-controlled, double-blind, three-way crossover phase. The main efficacy measures were the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale deportment scale and the Permanent Product Measure of Performance math test.All of the efficacy measures indicated that 4- and 6-hour wear times improved ADHD symptoms

2008 EvidenceUpdates Controlled trial quality: uncertain

194. Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response (Abstract)

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD).In a large placebo-controlled, double-blind study, patients ages 6-16 (...) with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind

2008 EvidenceUpdates Controlled trial quality: uncertain

195. Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD

Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Article Text

2008 Evidence-Based Mental Health

196. Maternal adiposity prior to pregnancy is associated with ADHD symptoms in offspring: evidence from three prospective pregnancy cohorts Full Text available with Trip Pro

Maternal adiposity prior to pregnancy is associated with ADHD symptoms in offspring: evidence from three prospective pregnancy cohorts We examine whether pregnancy weight (pre-pregnancy body mass index (BMI) and/or weight gain) is related to core symptoms of attention deficit hyperactivity disorder (ADHD) in school-age offspring.Follow-up of prospective pregnancy cohorts from Sweden, Denmark and Finland within the Nordic Network on ADHD.Maternal pregnancy and delivery data were collected (...) prospectively. Teachers rated inattention and hyperactivity symptoms in offspring. High scores were defined as at least one core symptom rated as 'severe' and two as 'present' (approximately 10% of children scored in this range). Logistic regression and latent class analyses were used to examine maternal pregnancy weight in relation to children's ADHD core symptoms.Teacher rated 12 556 school-aged children. Gestational weight gain outside of the Institute of Medicine guidelines was not related to ADHD

2008 EvidenceUpdates

197. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder (Abstract)

Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder This study compared once-daily dexmethylphenidate extended release (D-MPH-ER) 20 mg/day and placebo over 12 hours in children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting.All of the children were stabilized for > or =2 weeks on a total dose (nearest equivalent) MPH 40 mg/day or immediate-release D-MPH 20 mg/day before screening. After (...) hours, SKAMP subscale scores, and math test results over 12 hours.Sixty-eight children were randomized, with 67 completing the study. Onset of action was indicated by a significant difference between D-MPH-ER and placebo at 0.5 hour on the SKAMP combined score (p = .001). For efficacy measures, differences from placebo were significant at all points between 0.5 and 12 hours (p < .001 top = .013).D-MPH-ER provided sustained improvement in attention, deportment, and academic productivity throughout

2008 EvidenceUpdates Controlled trial quality: uncertain

198. Attention deficit hyperactivity disorder: diagnosis and management

Attention deficit hyperactivity disorder: diagnosis and management Attention deficit hyperactivity disorder: diagnosis and management | Guidance | NICE Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline [CG72] Published date: September 2008 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2008 National Institute for Health and Clinical Excellence - Clinical Guidelines

199. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. Full Text available with Trip Pro

Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. Stimulant medication can effectively treat 60% to 70% of youth with attention-deficit/hyperactivity disorder (ADHD). Yet many parents seek alternative therapies, and Hypericum perforatum (St John's wort) is 1 of the top 3 botanicals used.To determine the efficacy and safety of H. perforatum for the treatment of ADHD in children.Randomized, double-blind (...) , placebo-controlled trial conducted between March 2005 and August 2006 at Bastyr University, Kenmore, Washington, among a volunteer sample of 54 children aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria for ADHD by structured interview.After a placebo run-in phase of 1 week, participants were randomly assigned to receive 300 mg of H. perforatum standardized to 0.3% hypericin (n = 27) or a matched placebo (n = 27) 3 times daily for 8 weeks. Other

2008 JAMA Controlled trial quality: predicted high

200. Collaborative consultation increases use of medication titration trials but not behaviour in children with ADHD

Collaborative consultation increases use of medication titration trials but not behaviour in children with ADHD Collaborative consultation increases use of medication titration trials but not behaviour in children with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Collaborative consultation increases use of medication titration trials but not behaviour in children with ADHD Article Text Therapeutics Collaborative consultation

2008 Evidence-Based Mental Health